What is Terpen?
Terpen operates as a specialized biotech R&D enterprise, carving out a distinct niche within the competitive beauty and wellness landscape. By leveraging advanced scientific methodologies, the company has developed a diverse portfolio of therapeutic and cosmetic products, ranging from pain relief hot gels and roll-on freeze treatments to sophisticated massage oils, serums, elixirs, and wellness-focused gummies. The organization serves a growing demographic of health-conscious consumers who prioritize efficacy and innovation in their personal care routines. By bridging the gap between clinical-grade research and accessible consumer goods, Terpen maintains a robust market position, effectively addressing the rising demand for high-performance wellness solutions that offer tangible health benefits.
How much funding has Terpen raised?
Terpen has raised a total of $33K across 1 funding round:
Debt
$33K
Debt (2021): $33K with participation from PPP
Key Investors in Terpen
PPP
Public-Private Partnership
What's next for Terpen?
With the infusion of $33K, Terpen is poised to transition into a more aggressive scaling phase. The strategic deployment of this capital will likely focus on expanding manufacturing capabilities, enhancing supply chain resilience, and broadening the distribution footprint for its core product lines. As the company matures beyond its current Series B/C stage, leadership will likely prioritize clinical validation of its proprietary formulations to further differentiate its offerings in a crowded market. Future growth will depend on the firm's ability to maintain its R&D velocity while successfully navigating the regulatory complexities inherent in the biotech-wellness sector. By scaling its operational infrastructure, Terpen aims to solidify its status as a leader in the next generation of science-backed beauty and wellness products.
See full Terpen company page
